A Multicenter Open Label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levadopa Orally Disintergrating Tablets, Compared to Conventional Carbidopa/Levadopa Tablets in Subjects with Parkinson's

Grants and Contracts Details

StatusFinished
Effective start/end date1/20/04 → 12/31/04

Funding

  • Schwarz Pharma: $25,716.00